Every physician who hears about the Verdira model for the first time has the same reaction. Walk into full ownership of an established practice, put $0 down, carry no personal guarantee, take no 7-figure loan, and start earning from day one with patients already on the books. It sounds like a pitch that falls apart the second you ask a hard question.

The skepticism is rational. Every PE group that ever acquired an ophthalmology practice also sounded great in the first meeting with promises of autonomy, operational support, and above-market compensation. Then year 2 happened and the volume targets showed up.

So the right question is whether the math holds up when you look at the 3 conditions that make the structure work.

The Seller Needs an Exit and Can't Find One

There are approximately 4,300 solo ophthalmologists who will exit practice by 2030. These are physicians in their late 50s, 60s, and 70s who built practices over 20 to 30 years and have no succession plan. The young ophthalmologists who were supposed to take over either signed with PE groups, took hospital salaries, or decided that spending $600,000 to start from scratch while carrying $250,000 in student debt wasn't a risk they could afford.

Brokers who specialize in ophthalmology are sitting on 10 to 11 unsold practices each. The practices are profitable, the physicians want to retire, and there are no buyers because PE platforms pass on deals below their deployment minimums, hospitals don't want solo conversions, and individual buyers can't afford the upfront cost.

That supply-demand imbalance is the foundation. The seller is willing to structure a transition without a massive upfront payment because the alternative is closing the practice, sending a letter to their patients, and walking away from their life's work.

The MSO Handles Everything the Physician Can't Afford to Build

Starting an ophthalmology practice from scratch means hiring and managing a full staff, negotiating a facility lease, purchasing or leasing equipment, building out billing and collections infrastructure, setting up compliance systems, managing marketing and patient acquisition, and handling every regulatory requirement from state licensing to HIPAA to OSHA. The startup cost for all of that is roughly $600,000 before you see your first patient.

Under the Verdira model, that infrastructure already exists because the MSO acquires the non-clinical assets and manages every piece of the business that has nothing to do with patient care. The successor physician walks into a fully operational practice on day 1 with staff already trained, systems already running, and patients already scheduled.

The Practice Is Already Generating Revenue

This isn't a startup where you spend 2 years building a patient base from zero. An established ophthalmology practice with 20 to 30 years of history has existing patients, existing referral patterns, existing surgical volume, and existing insurance contracts, which means revenue is flowing before the successor physician ever performs a single procedure.

That's why the economics work without a massive upfront investment. The practice already pays for itself through existing cash flow, the MSA fee covers the operational side from that revenue, and the successor physician's income comes from the same revenue base. Nobody needs to inject capital to make the first year work because the money is already there.

How This Differs from PE

The surface similarity between "walk into an established practice and start earning" and a PE employment offer is where the confusion comes from, because both involve an existing practice, someone else handling operations, and day-1 income.

The difference is structural and it matters more than any number on a compensation page. In a PE deal, you're an employee. The PE group owns the management entity, controls the operations, sets the volume expectations, and keeps the equity. Your salary is fixed by contract and your clinical autonomy lasts exactly as long as it takes for the volume targets to show up in year 2. When the fund exits in 3 to 5 years, you find out what your contract actually said about what happens next.

In the Verdira model, you own the professional corporation, which is the clinical entity that holds the provider contracts, the patient relationships, and the right to practice medicine. The MSO provides operational services through an MSA with defined terms, defined scope, and defined fees. You aren't an employee of the MSO. You're the owner of the practice that the MSO serves. PE takes autonomy in exchange for convenience. This model provides the same convenience while you keep the autonomy because you own the entity.

Why the Math Works Anyway

The reason this sounds too good to be true is that nobody built this structure before. Nobody sat at the intersection of healthcare M&A, MSO architecture, and physician succession planning and decided to build it for the physician instead of for the fund. The seller needs an exit. The MSO absorbs the operational complexity. The practice is already generating cash flow. Those 3 things together produce ownership economics that outperform PE employment by $100,000 to $300,000 per year on the same practice. And ophthalmology is uniquely suited for this model because the AMA's 2024 Physician Practice Benchmark Survey found that 70.4% of ophthalmologists remain in private practice, the highest rate of any specialty surveyed, which means the culture of physician ownership already exists in this field even as it disappears everywhere else.

We broke down the full take-home math by subspecialty and revenue level in a separate piece. The short version: ownership on a $2M practice produces $500,000 to $700,000 in year 1 take-home versus $285,000 to $425,000 under PE employment. The long version with sources is on the blog, and you can pressure-test every number yourself at verdira.com/calculator.

Educational material only. Figures are illustrative and individual results vary. Images are AI-generated illustrations and do not depict actual Verdira practices, physicians, or patients. See our Disclosures.